Department of Neurology, Division of Movement Disorders, Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, Toronto, ON, Canada.
Department of Neurology, Division of Movement Disorders, Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, Toronto, ON, Canada.
Handb Clin Neurol. 2023;192:3-20. doi: 10.1016/B978-0-323-85538-9.00005-5.
Precision medicine is a patient-centered approach that aims to translate new knowledge to optimize the type and timing of interventions for the greatest benefit to individual patients. There is considerable interest in applying this approach to treatments designed to slow or halt the progression of neurodegenerative diseases. Indeed, effective disease-modifying treatment (DMT) remains the greatest unmet therapeutic need in this field. In contrast to the enormous progress in oncology, precision medicine in the field of neurodegeneration faces multiple challenges. These are related to major limitations in our understanding of many aspects of the diseases. A critical barrier to advances in this field is the question of whether the common sporadic neurodegenerative diseases (of the elderly) are single uniform disorders (particularly related to their pathogenesis) or whether they represent a collection of related but still very distinct disease states. In this chapter, we briefly touch on lessons from other fields of medicine that might be applied to the development of precision medicine for DMT in neurodegenerative diseases. We discuss why DMT trials may have failed to date, and particularly the importance of appreciating the multifaceted nature of disease heterogeneity and how this has and will impact on these efforts. We conclude with comments on how we can move from this complex disease heterogeneity to the successful application of precision medicine principles in DMT for neurodegenerative diseases.
精准医学是以患者为中心的方法,旨在将新知识转化为优化干预措施的类型和时机,从而使个体患者最大受益。将这种方法应用于旨在减缓或阻止神经退行性疾病进展的治疗方法中,引起了广泛关注。事实上,有效的疾病修饰治疗(DMT)仍然是该领域最大的未满足的治疗需求。与肿瘤学领域的巨大进展相比,神经退行性疾病领域的精准医学面临着多个挑战。这些挑战与我们对疾病许多方面的理解存在重大局限性有关。该领域进展的一个关键障碍是,常见的散发性神经退行性疾病(老年人)是否为单一的统一疾病(特别是与发病机制有关),还是它们代表了一系列相关但仍然非常不同的疾病状态。在本章中,我们简要探讨了可能应用于神经退行性疾病 DMT 精准医学发展的其他医学领域的经验教训。我们讨论了为什么迄今为止 DMT 试验可能失败,特别是理解疾病异质性的多方面性质以及这如何影响这些努力的重要性。最后,我们就如何从这种复杂的疾病异质性过渡到成功应用精准医学原则来治疗神经退行性疾病的 DMT 发表了评论。